Mahamaya Lifesciences Ltd

Mahamaya Lifesciences Ltd

₹ 114 -2.27%
21 Nov - close price
About

ncorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management.[1]

Key Points

Business Profile[1]
The company manufactures pesticide formulations and supplies bulk products to Indian agrochemical companies and multinational corporations (MNCs). It imports scientifically researched molecules, secures registrations with the Central Insecticides Board, and develops these molecules into technical-grade and value-added formulations, which are marketed to domestic manufacturers and global MNCs.

  • Market Cap 266 Cr.
  • Current Price 114
  • High / Low 122 / 111
  • Stock P/E 20.7
  • Book Value
  • Dividend Yield 0.00 %
  • ROCE 25.8 %
  • ROE 34.4 %
  • Face Value 10.0

Pros

Cons

  • Debtor days have increased from 52.0 to 66.6 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Mar 2024 Mar 2025
137 162 266
128 148 241
Operating Profit 9 13 25
OPM % 7% 8% 9%
0 1 1
Interest 3 6 7
Depreciation 1 1 2
Profit before tax 5 8 17
Tax % 28% 27% 26%
4 5 13
EPS in Rs 29.87 43.80 7.22
Dividend Payout % 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 64%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 136%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 34%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Mar 2024 Mar 2025
Equity Capital 1 1 18
Reserves 18 24 32
24 55 58
34 33 81
Total Liabilities 78 112 189
21 21 27
CWIP 2 3 4
Investments 0 0 0
55 88 157
Total Assets 78 112 189

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Mar 2024 Mar 2025
1 -23 -3
-3 -1 -4
3 25 8
Net Cash Flow 1 -0 1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Mar 2024 Mar 2025
Debtor Days 25 64 67
Inventory Days 109 137 167
Days Payable 90 61 92
Cash Conversion Cycle 45 140 142
Working Capital Days 14 15 30
ROCE % 21% 26%

Shareholding Pattern

Numbers in percentages

4 Recently
Nov 2025
56.35%
6.39%
4.67%
32.60%
No. of Shareholders 1,034

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Annual reports

No data available.